Oil penny stocks are among the hottest investments to watch at the moment as coronavirus outspread has deepened oil industry problems. Indeed, the record output cuts from OPEC+ failed to stabilize prices and investor’s sentiments because the steep drop in demand has been weighing on oil prices.

The oil demand dropped close to 25m barrels a day in March with expectations for a similar decline in April. Meanwhile, OPEC and its allies agreed to slash oil production by 9.7m barrels a day that will begin from May and extends to the end of June; the output cut will reduce to around 7m barrels a day through the second half of this year. The US President has also been playing a role in cutting supplies to blaster the prices, aimed at supporting the US oil industry that is providing hundreds of thousands of jobs to Americans.

The oil price selloff has wiped off close to 50% of the value of big oil companies year-to-date while small-cap oil stocks lost up to 90% or more in 2020. Brent crude is currently trading around $30 a barrel while US oil is hovering close to $20 a barrel.

However, oil prices are unlikely to trade in that range over the long-term as demand trends are likely to bounce back once the coronavirus impact fades. The production cuts would also help in strengthening prices and matching supply with demand. Therefore, it’s a perfect time to watch hot oil penny stocks that have the potential to stand taller during the pricing headwinds.

Chesapeake Energy

Chesapeake Energy stock price lost close to 90% of value since the beginning of this year on oil price volatility. Its shares are currently trading around $0.13 with the market capitalization of $310m. The massive debt load along with lower oil prices are weighing on Chesapeake Energy stock price performance. Its board has approved a 1-for-200 reverse stock split to comply with the $1/share minimum bid price requirement for listing on the NYSE. The company plans to make asset sales combined with big restructuring actions to face the pricing headwinds and to repay its debt.

Gulfport Energy

Gulfport Energy is a hot oil penny stock to watch because its stock price tumbled close to 75% this year on oil prices and debt crisis. It has $2bn of total debt at the end of the latest quarter while the available liquidity stood at $643m. The company has started looking at the options to service its debt load; Gulfport has started working with Perella Weinberg Partners and its energy advisory arm Tudor Pickering Holt for debt restructuring. Its revenue declined more than 30% in the latest quarter while the net loss came in at $11.36 per share.

Whiting Petroleum

Whiting Petroleum also stands among the oil penny stocks to watch because it was once the largest oil producer in North Dakota’s Bakken Shale. The company has recently filed for Chapter 11 bankruptcy protection. It currently has around $585m of cash on hand with $2.9bn of debt that includes a $770m of bond that matures next year. The company also claims that comprehensive restructuring actions will help it in reducing the debt and establishing a more strong capital structure.

Oasis Petroleum

Oasis Petroleum turned into a penny stock following the massive share price collapse in the past couple of months. The market analysts have downgraded Oasis ratings following the oil price slump in the last two months. Piper Sandler equity researchers provided an “Underweight” rating from earlier “Neutral” ratings. JP Morgan has also dropped OAS shares to “Underweight” rating. Its upcoming debt maturities and negative free cash flow generation could create problems for the company.

SM Energy

SM Energy shares price fall of 80% this year has forced the company to slashed its dividend by 80% to save cash in the wake of lower oil prices. Its oil production accounted for 45% of fiscal 2019 total production of 48.3 MMBoe. The company had generated more than $800m in operating cash flows last year which helped it in dropping net debt-to-adjusted EBITDA to 2.8 times.

The coronavirus pandemic is wreaking havoc across the world, death tolls are rising at an alarming rate and stock markets experiencing wild swings that are making investors nervous. Millions of workers have been laid off and businesses are shutting down as every country has had no choice but to enforce a lockdown. Despite all the terrible consequences caused by COVID-19, it has opened up opportunities to buy penny stocks with good fundamentals that should survive the coronavirus crisis.

Below we have put together a list of five penny stocks worth watching over the coming months – make sure to perform your own research before investing and don’t trade with money you can’t afford to lose.

EVRI – Everi Holdings Inc

Everi Holdings Inc. provides technology solutions for the casino gaming industry in the United States, Europe, Canada, the Caribbean, Central America, and Asia. The company operates in two segments, Games and FinTech. This stock has weakened more than 60% since March 2020 and according to the rules of technical analysis, the “bearish” trend of this stock is still very strong. Despite this situation, this stock could make a very big jump in the next several weeks and this stock should be on the watchlist of every trader who follows penny stocks. Total revenues in 2019 were $533.2 million, growing by 13% from 2018. The management of this company believes that Everi Holdings Inc will drive long-term revenue growth and improved profitability in the upcoming years.

OGI – OrganiGram Holdings Inc

OrganiGram Holdings produces and sells cannabis and cannabis-derived products in Canada. This company offers cannabis flowers, cannabis oils, and pre-rolls for adult recreational consumers under several brands. This stock has weakened more than 30% since March 2020 and according to the rules of technical analysis, the “bearish” trend of this stock is still very strong. According to analysts, the legal cannabis industry is expected to advance and it may even hit the $200 billion mark by the end of the decade. It is also important to mention that this stock has lost nearly two-thirds of its value over the prior 12 months. This sharp sell-off had little to do with internal operations or financial performance of OrganiGram during this period. Total revenues in 2019 were $60.4 million, growing by 534% from 2018. If you’re looking to invest in the cannabis industry, OrganiGram is probably a great choice because this stock is cheap for a high-level cannabis company with solid fundamentals.

Fluent Inc. FLNT

Fluent, Inc. provides data-driven digital marketing services primarily in the United States. The company also offers customer acquisition services by operating digital marketing campaigns, through which the company connects its advertiser clients with consumers. This stock has weakened more than 30% since March 2020 and according to the rules of technical analysis, the “bearish” trend of this stock is still very strong. Despite this situation, this stock could make a big jump in the next few weeks. Total revenues in 2019 were $281.7  million, growing by 13% from 2018. It is also important to mention that EBITDA was $11.5M (14% of revenues) while adjusted net income rose to $6.12M from a year-ago $5.99M.

ZIXI – Zix Corporation

Zix Corporation provides email encryption, data loss prevention (DLP), threat protection, archiving, and bring-your-own-device mobile security solutions for the healthcare, financial services, insurance, and government sectors primarily in the United States. The price of this stock has advanced from $3 above $5 in less than three weeks but despite this,  Zix Corporation boasts over 20,000 customers, and a cloud app that is used by 30% of US banks. Yes, it is true that the price of this stock could fall again but according to some predictions, this stock could be above $8 after coronavirus passes.

ORBC – ORBCOMM Inc

ORBCOMM Inc. provides Internet of Things solutions in the United States, South America, Japan, Europe, and internationally. This stock has weakened more than 50% since the beginning of the 2020 year and according to the rules of technical analysis, the “bearish” trend of this stock is still very strong. Total revenues in 2019 were $272 million, falling by 1.49% from 2018. Despite this, the management of this company believes that ORBCOMM will drive long-term revenue growth and improved profitability in the upcoming years. According to analysts, the company expects to see stable services revenue based on the fact that its products and services track refrigerated trucks and containers that carry 60% of the world’s food supply. Amid the worsening COVID-19 pandemic, there’s clearly a high demand for grocery stores, one of few businesses benefitting from the current crisis.

Here are some of the best pot penny stocks to follow in 2019 because of the growing acceptance towards marijuana. As of right now, 11 states have voted to legalize the recreational use of the drug. Other nations such as Canada also legalized the medicinal use of the plant which opens up more investment opportunities. Most small cap MJ companies don’t deserve such crazy valuations and are financial train wrecks destined to fail in the long term. People new to the stock market are investing $500 expecting to make a fortune when in reality these stocks are terrible investments. They are struggling to survive, crippled with debt and have very little revenue to support operations. I’ve seen old defunct mining companies just add the word “Cannabis” to their name to cash in on the craze. If you’re going to trade these stocks don’t get caught holding the bag.

Marijuana Penny Stocks to Follow

Cara Therapeutics Inc (NASDAQ:CARA)

Founded in 2004 and headquartered in Shelton, Connecticut, this clinical-stage biopharmaceutical company develops product candidates targeting the body’s peripheral nervous system. I.V. CR845, Cara’s lead product candidate, is in Phase III clinical trials, designed to treat acute postoperative pain in adult patients. Cara Therapeutics is also engaged in developing lead molecules that are supposed to selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. It’s most advanced CB compound is CR701, which is currently in a stage of preclinical development for treating neuropathic and inflammatory pain. The company will benefit because the development of marijuana-based analgesics is anticipated to shift toward CB2 receptors. Since recommending CARA as a buy at $5.97 it has gone on a wild ride, peaking at $26.95 in July and plunging back down to the $12 range. While they are still in the early stages of growth I think it has the potential for explosive gains providing you can handle the wild swings.

AURORA CANNABIS INC (OTCMKTS:ACBFF & TSE: ACB)

The Vancouver based company is engaged in cultivating, harvesting, and selling medical marijuana in Canada. It uses water from the Canadian Rocky Mountains to bring the cannabis plants to harvest in their 55,200 square feet facility. Aurora Cannabis provides high-quality medical cannabis, offering the following prices to its patients: (1) $8/gram strain pricing, (2) $5/gram composite pricing. It also offers free shipping in Canada. The company’s stock price has grown more than 300 percent since I first posted about the business and looks like it will continue. With Canada planning to legalize marijuana on July 1st, 2018, the company is attempting to gain a top spot with strategic acquisitions. Aurora are buying up competitors as they want to dominate production and retail. Aurora are now trying to takeover their biggest rivals, CanniMed. If the acquisition goes through it would increase Aurora’s production capacity to nearly 135,000 kg every year. Even if the CanniMed acquisition fails Aurora will continue buying up smaller players and consolidate their position in the industry. Expect shares to be volatile in the near future!

Canopy Growth Corporation (OTCMKTS:TWMJF & TSE:WEED) 

Canopy Growth, formerly known as Tweed Marijuana Inc., is the largest producer of medical marijuana in Canada. It is engaged in production and sales of medicinal marijuana under its Tweed and Bedrocan brands. Over the last 12 month, they have been aggressively acquiring smaller Canadian licensed producers. Since the start of the year, their stock price has soared from $7 to $14.20! Canopy Growth boasts 665,000 square feet of indoor greenhouse production capacity. After numerous acquisitions, their production capacity now stands at an impressive 40,000 kilograms per year. Increasing production capabilities is crucial as demand will soon overtake supply once recreational use of the plant is allowed in 2018. Despite the companies phenomenal growth I think they are overvalued and shares will pull back. Although they face challenges in the future they are well positioned to capitalize on huge demand for various marijuana products within Canada.

Aphria Inc (OTCQB:APHQF & TSE:APH)

Aphria Inc is another big player in the medical cannabis sector set to profit from the developing Canadian market. They sell and transport medical cannabis oil to customers globally. Aphria recently spiked 20% on the news of receiving a dealer’s license from Health Canada. This license allows them to expand rapidly into the international market and decrease their dependence on their home nation. Since 2015 revenue has grown significantly from $550,000 to over $20 million (CAD) so far. Net income was $15 million which is rare for a cannabis company to be profitable. Similarly to other businesses in the sector they are ramping up production. Aphria purchased a position in a Florida OTC marijuana stock, Liberty Health Sciences, to gain more exposure to the green rush! Their low productions costs, strong earnings, and solid growth make them an exciting investment.

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

Founded in 2007, this pharmaceutical company is focused on developing and commercializing synthetic cannabinoid therapeutics developed for transdermal delivery. Its two product candidates are ZYN002 and ZYN001. ZYN002 represents a synthetic cannabidiol (CBD), a permeation-enhanced gel for transdermal delivery, made to provide controlled drug delivery with once- or twice-daily dosing ZYN001, which enables transdermal delivery through a patch, is intended to be tested for application to the arm, back and thigh. The company will study ZYN001 for the treatment of fibromyalgia and peripheral neuropathy. The stock price is very volatile as Zynerba race to become the first FDA approved marijuana-based treatment ahead of GW Pharmaceuticals. It’s worth noting, Zynerba’s pipeline is still in the early stages of development. Investors can only hope studies on treating autism and epilepsy continue to release positive results. At some point, they will have to raise more money but for now, have enough capital to sustain operations for another two years. I would wait until more studies are available before adding this company to your portfolio.

American Cannabis Company Inc (OTCMKTS:AMMJ)

The company, incorporated in 2001, provides solutions for pot industry businesses in the U.S. and Canada. The company’s operations can be divided into two main components: (1) advisory and consulting services, and (2) sale of products and equipment for customers in the cannabis industry. The offered consulting services include commercial business planning, business license applications, cultivation build-out consulting, regulatory compliance, compliance audit services, business growth strategies, and business monitoring services. In addition to its consulting business, the company provides products and equipment such as Satchel, SoHum Living Soil, High Density Racking System and The Cultivation Cube. American Cannabis Co was one of the biggest runners in 2016, the penny pot stock went from $0.11 to $1.50 and now trades at $0.79. Now AMMJ only has a market cap of $40 million with last quarters earnings set at $0.99 million. Risky investment due to how small the business but definitely an opportunity worth following.

Cannabis Sativa Inc (OTCMKTS:CBDS)

The company is based in Nevada and has been in operation since 2005, though it only went public three years ago. Cannabis Sativa develops and promotes natural cannabis products through its online website and Amazon. A number of their products contain CBD, a chemical compound found in hemp plants that potentially have medicinal uses. This tiny penny weed stock has the license for a medicinal cannabis strain, namely NZT, a cannabis lozenge delivery technique and a cannabis trauma cream formula. No longer recommend investing as revenue is disappointing and insiders are slowly selling shares. A classic example of a company with very little assets that only exists so shareholders can enrich themselves from all the hype.

Medical Marijuana Inc (OTCMKTS:MJNA)

Incorporated in 2005, and still being in its development stage, the company provides a wide range of products, services and technologies for the medical marijuana and industrial hemp sectors. These include cannabinoid-based products, such as cannabinoid chewing gum, new extraction technologies, and isolated high value extracts developed for the pharmaceutical, cosmetic and nutrition industries. Despite enjoying strong gains over the years the penny stock has lost 90% of its value since its IPO back in 2009.

Terra Tech Corp (OTCMKTS: TRTC)

Terra Tech Corp is a medical marijuana penny stock that focuses on cannabis agriculture and is located in Irvine, California. They design and sell hydroponic equipment along with their proprietary technology for the cultivation of indoor agriculture. TRTC operates through various subsidiaries including MediFarm, IVXX, Blüm and Edible Garden. While Terra Tech’s revenue is growing nicely they aren’t profitable yet. In Q3, total revenue was $10.1 million, up $3 million in the same period from the previous year. The net loss was $7.8 million with future financial updates expected to improve after investing heavily in expansion throughout California.

Kush Bottles (OTCMKTS:KSHB)

Kush Bottles is a start-up based in California that helps entrepreneurs enter the cannabis business. They provide an all-in-one solution to help reduce the barriers to entry in an industry that is heavily regulated. Kush is one of the biggest distributors of marijuana packaging and supplies. The company provides an indirect opportunity to profit from a booming sector potentially worth $20 billion by 2020. Remember the people who really made money during the gold rush were those who sold supplies. Kush is currently profitable with no debt and steady earnings. The only downside is their margins are quite low.

Bitcoin’s whopping 260 percent surge this year is setting the stage for a potentially even bigger upswing. Some analysts are predicting that Bitcoin, the most widely traded cryptocurrency, will trade at $21,000 levels by the end of 2019, meaning that the party may not be over yet. And one easy way to get a piece of the action is to invest in blockchain penny stocks. Here are my top picks:

Grayscale Bitcoin Trust (GBTC:OTCQX)

It reportedly holds about 1.2 percent of Bitcoin in existence. As Bitcoin prices rise, expect Grayscale to follow suit. The trust, whose assets under management were hovering near the $3 billion mark at the end of June, only owns Bitcoin, meaning that any continuation in the current trends seen with Bitcoin will surely benefit Grayscale as well. Oh, and did I mention it was trading at roughly $4 in January?

Riot Blockchain Inc. (RIOT:NASDAQ)

It utilizes about 8,000 specialized computers to run its own Bitcoin mining operation. The upside looks good. But there’s also that SEC investigation regarding public disclosures and ownership that’s still ongoing, and it could put impact the stock price as and when we hear updates on this front. Riot Blockchain is also planning to launch a cryptocurrency exchange, RiotX, later this year, which will give customers the ability to trade in Bitcoin, Ether, Litecoin, etc.

MGT Capital Investments Inc. (MGTI:OTCQB)

The only reason this cryptocurrency mining firm made my list is because I believe it will ride the expected Bitcoin wave in the foreseeable future. The company had briefly stopped mining Bitcoin citing difficult economic conditions but said in May that the recent increase in the price of Bitcoin allowed it to resume its mining operations. There is also plenty of volatility in the share price to capitalize on. Proceed with caution, as its fundamentals are not appealing.

Marathon Patent Group Inc. (MARA:NASDAQ)

The company boasts of being one of the first Nasdaq-listed cryptocurrency mining companies. But that’s about all it can boast about. It currently operates only one mining facility (though it hopes to open more at some point). However, the technicals on its share price look promising. Another company whose stock price volatility is worth tracking.

These blockchain companies tend to mirror Bitcoin’s price moves, or at the very least get caught up with the hype of Bitcoin’s price fluctuations and rallies. While the Bitcoin rally party is already underway, jump in now with blockchain penny stocks and your party could be just about starting.

If analysts are to be believed, then we could see a return to Bitcoin prices charging on to new records, even beyond the all-time highs that we last saw in December 2017. However, it is bound to be a bumpy ride to get there. We’ve already seen the cryptocurrency darling lose some steam in the past week, losing nearly a fourth of its value since touching a 2019 high at the end of June. Further correction is expected in the near-term as traders book profits. And surprise, surprise. The companies listed above rose and fell with Bitcoin, with the price charts of Grayscale Bitcoin Trust and Riot Blockchain fluctuating along similar lines as that of Bitcoin.

To maximize gains, a combination of a conventional buying-and-selling approach, coupled with building periodic short positions, would be an optimal investment strategy for trading in blockchain penny stocks. We can expect to see more volatility ahead as momentum builds up for Bitcoin, and by extension, for these related stocks. At the same time, there is bound to be a healthy mix of upswings and corrections that also occur along the way as technical thresholds are breached. These blockchain penny stocks provide a useful entry point to benefit from the anticipated Bitcoin bull-run forecast for the coming months, especially for those who are unable to mine Bitcoin itself.

Eastman Kodak Co (KODK:NYSE)

If however, the Bitcoin euphoria isn’t for you, you could look at Eastman Kodak Co (KODK:NYSE) as an investment opportunity. The company that was once synonymous with photography, recently launched a blockchain-based document management platform for businesses, which Kodak claims will offer significant cost savings to its users. KodakCoin, a cryptocurrency being developed under Kodak’s brand, in partnership with some other firms, is also due to be launched soon. Of course, this could also be the company’s attempts to reap the benefits of the excitement surrounding all things related to blockchain and cryptocurrency. But if you’re a believer, buying Kodak’s shares now could mean getting in on the ground floor. If you’re skeptical and smell some blood in the water, you could also join the investors shorting Kodak, who as of last month had positions on roughly 14.5 percent of its outstanding shares.

Technology stocks have risen in prominence over the last few years as blue-chips stars like Apple, Inc. (NASDAQ: AAPL), Facebook (NASDAQ: FB), and Amazon, Inc. (AMZN) have taken priority in most of the financial news media. But if you are looking for companies with true growth prospects, there are many promising technology penny stock companies on the rise that are ready to explode! Here, we will look at some of the best penny tech shares to buy in 2017. All of the stocks on our list will be looking to profit from hot trends such as artificial intelligence, drones, cloud computing, healthcare and cyber security. (Also make sure you checkout my other article to see what biotech stocks you should be following)

Arotech Corp.​ (NASDAQ: ARTX)

Arotech Corp.​​ is moving forward in two of today’s most important technology trends: virtual reality and drone devices. The company produces training programs in ​use-of-force simulations​ for law enforcement and the military. Contract values have been growing for Arotech, and this is expected to continue with its security systems and solutions for the emergency services industry.

Going forward, markets are likely to focus more attention on Arotech’s aircraft and missile systems, in addition to its weapons simulations. These programs are being designed to build on the revenue that are already being generated by its strong positioning in surveillance and military services. Drone technologies have been getting increasing attention in the financial news media and Arotech’s developments in artificial intelligence has pushed the company ahead of most of its small-cap competition.

Revenues have lagged over the past four quarters on falling operating income performances but this has led to declines in the stock that create buying opportunities for growth investors looking for ways to ​build low-cost exposure​ to the sector. The company currently shows a market cap

of $93.41 million, and a P/E Ratio (TTM) of -31.30 which is a significant indicator suggesting the company remains undervalued.

Transgenomic, Inc.​ (TBIO)

Next, we look at Transgenomic, Inc., which saw dramatic gains this year when the company’s ICE COLD-PCR​ cancer testing agent was officially licensed by ​LifeLabs.​ The breakout generated gains of almost 300% in the stock and actually managed to hold onto most of those gains after the initial pullback. This, along with the surges in volume (which were much higher than the historical averages), suggest that the moves are real and that long-term gains in store for Transgenomic.

The company has managed to survive with negative operating income, and investors tripled income levels after the deal with LifeLabs was announced. Going forward, the revenues driven by these deals will be the ​key indicator ​of potential stock performance and so investors will be looking at these areas in their assessments over the next several quarters.

Zix Corp. ​(NASDAQ: ZIXI)

Zix Corp. is an email services provider, with products that help to ​secure messaging​ for government entities and corporations. The company has posted some strong innovations in its encryption methods, which help to protect against unauthorized downloading that enable cyber attacks.

Zix has posted sales increases of 65% over the last five years, and if these trends continue we will probably see the stock exit the ‘penny stock’ category very soon. Zix currently has a market cap of roughly $315 million and its earnings-per-share continues to show positive results. The stock’s P/E ratio is elevated at 52 but growing revenues should keep this company on the radar for growth investors.

Rennova Health, Inc. ​(NASDAQ: RNVA)

Rennova Health, Inc. provides revenue cycle management software and medical diagnostics programs for laboratories. The company currently falls into the micro-cap category, with its market-cap of $7.98 million, and its operating income reports have been somewhat volatile over the last year. Rennova recently offered 12,350 shares of Series H convertible preferred stock, driving valuations down to new lows — and creating new buying opportunities for growth investors.

Going forward, upside growth could be seen on its recent ​decisions to buy diagnostics company Genomas​ as well as several hospitals — and this should help to stabilize some of the volatility that has been seen in the stock over the last few months.

Sphere 3D Corp. ​(NASDAQ: ANY)

Sphere 3D Corp. is a tech company that sells cloud-based data storage to businesses. Its innovations in desktop management and data storage are sold in the US, Asia Pacific, and European regions, and we are seeing positive developments in earnings trends its since inception.

Sideways trading activity in the stock suggests a period of consolidation that could be used as a base for new positions that could benefit from several deal arrangements that are currently in the pipeline. The company’s diversified client base makes it an excellent candidate for a takeover buyout, and so we expect Sphere 3D to start gaining more attention within the market as long as its revenue trends continue to expand.

As always, investors considering these stocks should prepare for potential volatility with market valuations holding at relatively low levels. But if you are a growth investor looking for new opportunities in the sector, each of these companies is well-positioned for further moves higher.

Investing in biotech penny stocks is one of the most exciting and dangerous sectors of the stock market, it definitely isn’t for the faint-hearted! These kind of stocks are so volatile as their value is largely attributed to products gaining FDA approval. You could lose 90% of your money by picking a biotechnology company that fails to get FDA approval. Curing diseases is big business and millions are made and lost based on one decision. In what other industry can a business burn through hundreds of millions of investors money and end up with nothing to show for all their effort? Despite all the risks, the healthcare market offers a massive opportunity for astute investors willing to perform their own due diligence and not get caught up in the hype of making 2000% gains overnight. Below is my list of some interesting biotech’s to watch this year, remember only invest money you can afford to lose. 

1. Apricus Biosciences Inc (NASDAQ: APRI) is a bio-pharmaceutical company creating new innovative medicines focusing on treating urology and rheumatology. Their share price is currently trading at $1.08 and has a 52 week high of $4.94 with a low of $0.86.

Apricus Biosciences has two products in the pipeline – Vitaros and Rayva. Vitaros is a fast acting cream to treat those unfortunate guys who suffer from erectile dysfunction. The product is currently approved for commercialization in Europe and Canada and is in development in the US. Their rights and assets have been sold to Ferring Pharmaceuticals. US NDA RE-Submission is expected in the third quarter of 2017 and has huge sales potential.

Apricus Biosciences released last quarter results on May 11, 2017. Net income was $8.1 million compared to a net loss of $2.5 million for the first quarter of 2016. EPS was $1.04 compared to a loss per share of $0.46. Net income was high due to the gain recorded in the sale of assets to Ferring Pharmaceuticals. Cash at the end of the first quarter is $10.6 million compared to $2.1 million as of December 31, 2016. Analysts estimate EPS to grow 70% this year and 147% in the next year.

2. MannKind Corporation (NASDAQ: MNKD) is a biotechnology company that develops therapeutic products to treat various types of diabetes and cancer. MannKind Corp is currently trading at $1.24 with a 52 week high of $5.10 and a low of $0.67. 

The company’s main product is FDA-approved AFREZZA, the only inhaled insulin on the market to help adults control blood sugar levels during mealtime. AFREZZA reaches it’s maximum effect after just 12-15 minutes and can stay active in the body up to three hours after use. They’ve started aggressively promoting the product via TV advertisements to raise awareness within the US and educate diabetics that insulin doesn’t just have to be injected. Despite disappointing initial sales figures, sales are starting to pick up and MannKind has enjoyed a solid start to Q2. 

Another medication in the pipeline is an inhalable epinephrine to treat to patients who suffer life threatening allergic reactions. Although the product is still in the early stages of development it could potentially be a cheaper alternative to Mylan’s EpiPen. An inhalable version of epinephrine could disrupt the marketplace that is dominated purely by EpiPen but this could take years to get approved by the FDA and will rely on sales of AFREZZA to vastly improve. 

The company released its last quarter results on May 10, 2017. Revenues for the first quarter were $3.0 million and deferred revenue of $1.8 million. They did not report revenues for the same quarter last year. Net loss for the quarter was $16.3 million when compared to net loss of $24.9 million for last year. EPS of -$0.17 compared to -$0.29. EPS is expected to grow 130% this year and 8% next year. Cash at the end of quarter was $48 million when compared to $22.9 million at the end of December 2016. They recently made significant changes to their management team so they’re better equipped to deal with growth.         

3. CorMedix Inc (NYSE: CRMD) is a pharmaceutical and medical device company focused on developing and commercialization of therapeutic products for the prevention and treatment of cardiorenal disease. CorMedix is currently trading at $0.39. It has a 52 week high of $3.26 and a low of $0.36.

CorMedix’s main product Neutrolin, is a non anti-biotic solution that prevents infections and thrombosis associated with central venous catheters. It is CE mark certified in certain European countries. The company recently entered into commercial collaboration with French based company Hemotech SAS, which will market the product in France and other European countries. In the US it is in Phase 3 stage. It has been granted FDA fast track status which would enable CorMedix to meet the officials more often and was identified as a Qualified Infectious Disease Product (QIDP), granted 10.5 years of potential market exclusivity. According to the estimates of WHO, US has about 250,000 Catheter-related blood stream infections and the cost is about $25,000 per infection.

The company released its last quarter results on May 11, 2017. It reported a net loss of $7.6 million compared to net loss of $4.1 million for the same period last year. With the recent Europe collaboration we should expect company to report revenues soon. The EPS is expected to grow 33% next year.

4. Viking Therapeutics Inc (NASDAQ: VKTX) is a promising clinical stage biopharmaceutical company dedicated to treating patients with metabolic and endocrine disorders. Viking Therapeutics is now trading at $1.16 with a 52 week high of $1.70 and a low of $0.90.

Viking Therapeutics has exclusive worldwide rights of five therapeutic programs in clinical trials and preclinical trials based on small molecules licensed from Ligand Pharmaceuticals. Company’s lead clinical program is VK5211, orally available, non-steroidal selective androgen receptor modulator (SARM) in Phase 2 development for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing selective thyroid receptor beta agonists for lipid disorders. Lead candidates are VK2809 and VK2014. It is targeting patients suffering from hypercholesterolemia, fatty lever disease, and X-ALD.VK0612 is developed with a main target of diabetes patients. Erythropoietin (EPO) acts on its receptor to stimulate the differentiation of bone marrow hematopoietic cells to form red blood cells. Ideally this is targeted to treat anemia patients. DiacylGlycerol Acyl Transferase-1 (DGAT-1) mediates absorption of fats from the gastrointestinal tract.

Viking Therapeutics released its last quarter results on May 10, 2017. Net loss for the quarter was $3.5 million compared to net loss of $1.9 million for the same period last year. Expenses increased due to clinical trials. They have made strong progress in the trails in the recent quarter. The cash at the end of the quarter was $12.3 million. EPS is expected to grow 76% this year. The company made a direct offering with accredited investors on June 14.

5. Catalyst Biosciences (NASDAQ: CBIO) is a clinical stage biopharmaceutical company focused on treating patients with hemophilia. Catalyst Biosciences is trading at $4.24. It has 52 week high of $28.50 and low of $3.64.

Factor VIIa marzeptacog alfa (activated) drug for the treatment of patients with hemophilia with inhibitors is expected to enter Phase 2/3 clinical trials in the fourth quarter of 2017. Factor IX CB 2679d/ISU304 is another drug in clinical trial stage. The company has partnered with ISU Abxis is targeted with patients with hemophilia B.

Catalyst Biosciences released its last quarter results on May 11, 2017. Contract revenue for the first quarter 2017 was $0.3 million compared to $0.1 million for the same period last year. Net loss was $4.1 million compared to $3.6 million for last year.EPS was -$4.57 compared to -$4.71 for last year. EPS is expected to grow 57% this year and 23% next year. Cash at the end of the quarter was $14.5 million and the company anticipates that the cash available is enough to sustain for the next 12 months.